David E Amacher
Research Subjects
Research Interests
David E Amacher has a total of 2 co-authors. Here are the top co-authors by number of shared publications:
- Jiri Aubrecht
Takeda Pharmaceuticals International Co., Cambridge, 02139 MA, USA
1 shared publication - Shelli J. Schomaker
Drug Safety R&D, Pfizer Inc., Groton, CT
1 shared publication
Latest Publications
- Open Access
- 27 September 2013
- Published by Springer Nature in Genome Medicine
- Vol. 5 (9) , 85-3
Emerging hepatotoxicity biomarkers and their potential to improve understanding and management of drug-induced liver injury
Biomarkers of drug-induced liver injury (DILI) are essential for the diagnosis of severe cases of DILI in clinical trials and clinical practice, but the currently used biomarker paradigm detects damage after it has occurred and has limited prognostic value. The development of new biomarker strategies that improve the diagnosis of DILI by providing increased specificity and/or by identifying individual patients who are at risk for DILI is therefore crucial. See related Research, http://genomemedicine.com/content/5/9/86
- 27 September 2013
- Published by Springer Nature in Genome Medicine
- Vol. 5 (9) , 85-3
Open AccessEmerging hepatotoxicity biomarkers and their potential to improve understanding and management of drug-induced liver injury
Biomarkers of drug-induced liver injury (DILI) are essential for the diagnosis of severe cases of DILI in clinical trials and clinical practice, but the currently used biomarker paradigm detects damage after it has occurred and has limited prognostic value. The development of new biomarker strategies that improve the diagnosis of DILI by providing increased specificity and/or by identifying individual patients who are at risk for DILI is therefore crucial. See related Research, http://genomemedicine.com/content/5/9/86